| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue studied in …STUDIED_INderived169 of 169show fewer |
|---|
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06647732Phase 2 · active not recruiting Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02494700Phase 2 · active not recruiting Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07705308Phase 2 · not yet recruiting A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339922Phase 2 · active not recruiting Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07376330not yet recruiting Molecular and Cellular Characterization of MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07609355NA · not yet recruiting AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07554898Phase 2 · recruiting Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01384513Phase 2 · completed A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03680586early Phase 1 · active not recruiting Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223765Phase 1 · recruiting Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01808599Phase 2 · active not recruiting Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06569680Phase 2 · recruiting Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796998Phase 2 · recruiting Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03147885Phase 1/Phase 2 · active not recruiting Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07144657Phase 2 · not yet recruiting Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04578600Phase 1 · completed CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03078855Phase 3 · completed A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01588015Phase 1 · completed Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06228963Phase 2 · recruiting Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01044745Phase 2 · terminated Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907447unknown A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00783367Phase 2 · completed Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635683Phase 1 · withdrawn Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01514344Phase 2 · completed Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02049541Phase 1 · completed Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01261247Phase 2 · completed Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05003141Phase 1 · unknown PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04465162Phase 2 · completed Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805037Phase 1/Phase 2 · terminated Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02037256NA · completed Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00536601NA · completed High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01678443Phase 1 · terminated Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00489203Phase 2 · completed Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01075321Phase 1/Phase 2 · completed Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00082888Phase 2 · completed Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00918333Phase 1/Phase 2 · completed Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00040846Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089011Phase 2 · completed Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006251Phase 1/Phase 2 · completed Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00014235NA · completed Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00078858Phase 1/Phase 2 · completed Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239875early Phase 1 · completed Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003196NA · completed Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01326702Phase 1/Phase 2 · completed Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02254772Phase 1/Phase 2 · completed A Phase I/II Study of Intratumoral Injection of SD-101 · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02652715NA · completed Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00856388NA · completed Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01529827Phase 2 · completed Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005799NA · completed Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01839916Phase 2 · completed Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03999697Phase 1 · unknown A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01159067Phase 2 · terminated Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01408043NA · terminated Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00210353Phase 3 · completed Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00711828Phase 2 · completed Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01093586Phase 2 · completed Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01273766Phase 2 · completed Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00012298Phase 1/Phase 2 · terminated Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01789255Phase 2 · completed Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01484015Phase 1 · completed Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168907Phase 1 · terminated CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01812005Phase 2 · terminated Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01129193Phase 1 · completed AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567709Phase 1 · completed Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00253630Phase 2 · completed Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00867529Phase 2 · completed Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01611259Phase 2 · completed Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682044Phase 2 · completed Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01254578Phase 1 · completed Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00073918Phase 2 · completed Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01419795Phase 2 · terminated Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00072514Phase 2 · completed Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01076270NA · terminated Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118352Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00088881Phase 2 · terminated Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00601718Phase 1/Phase 2 · completed Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112593NA · completed Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110135Phase 2 · completed Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00795769Phase 2 · completed Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00244855Phase 2 · completed Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427881Phase 2 · completed Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00049504Phase 2 · completed Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00408681NA · completed Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02987127unknown Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01015248Phase 2 · completed Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02281279Phase 1/Phase 2 · withdrawn Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112723Phase 1/Phase 2 · terminated Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00117156Phase 2 · completed Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01652014Phase 2 · withdrawn Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00201422NA · completed Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00327132NA · completed Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00438880Phase 1/Phase 2 · completed Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01748721Phase 1 · completed MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01045928Phase 1 · terminated Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109224Phase 1 · terminated Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658319Phase 1 · completed Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959477early Phase 1 · completed Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01583699NA · completed Endomicroscopy and Gastric MALT-lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00608361Phase 1 · completed Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00720135Phase 1 · completed Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769911NA · withdrawn Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003210Phase 2 · completed Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00210392Phase 2 · terminated VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00343798Phase 1 · completed A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00082784Phase 1 · completed Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01158274Phase 1 · completed RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00275080Phase 1 · completed Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00110071Phase 1 · completed Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00621452Phase 1 · completed Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089076Phase 1/Phase 2 · terminated MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054639Phase 2 · completed Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00290472Phase 2 · completed CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01233921NA · completed Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00890747Phase 1 · completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00096005Phase 1 · terminated Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00499811Phase 1 · completed Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00458731Phase 1 · completed Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769288Phase 1 · completed FAU in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00656812Phase 2 · completed Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00019708Phase 1 · terminated Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00373906Phase 2 · completed Velcade in MALT Lymphoma Patients · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00068315Phase 1 · completed Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00293345Phase 1 · completed 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00026182Phase 2 · completed Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00010192Phase 1 · completed Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01238146Phase 1/Phase 2 · withdrawn Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00017472Phase 1 · completed Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00058227Phase 1 · completed Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00103272Phase 1 · terminated 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054483Phase 1 · completed Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354185Phase 1 · terminated PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00348985Phase 1 · completed PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004241Phase 1 · completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00025415Phase 1 · completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005786NA · terminated Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00060112Phase 1 · terminated Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089271Phase 1 · completed 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003970Phase 1 · completed Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00077155Phase 1 · completed Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00098891Phase 1 · completed MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00005950Phase 2 · terminated 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006473Phase 2 · completed Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00101244Phase 1 · terminated SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00058305Phase 2 · completed Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00891072Phase 1 · completed Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00017381early Phase 1 · completed Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118170Phase 1 · completed Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01558778NA · withdrawn Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00799461Phase 3 · completed Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01302912unknown Lymphoma in the Orbit · condition mapped ONTOLOGY_EXACT · 169 trials mapped (24 active) | — | — | Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116154Phase 1 · terminated Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00923663Phase 2 · unknown Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01177371Phase 2 · completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00210327Phase 2 · completed VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00373646Phase 2 · completed Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients · condition mapped ALIAS · 169 trials mapped (24 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 1 | Observed | clinicaltrials | graph → |